Ensysce Biosciences, Inc. Common Stock (ENSC) is a publicly traded Healthcare sector company. As of October 16, 2026, ENSC trades at $0.57 with a market cap of $10.92M and a P/E ratio of -0.10. ENSC moved -5.50% today. Year to date, ENSC is -36.39%; over the trailing twelve months it is -75.79%. Its 52-week range spans $0.23 to $5.72. Rallies surfaces ENSC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ensysce submits UK MHRA Phase 2a trial protocol for CRPS drug candidate CY200: Ensysce submitted a Phase 2a protocol for CY200 in complex regional pain syndrome type 1 to the UK MHRA for regulatory review. The planned UK study will be randomized, double-blind and placebo-controlled, assessing efficacy, safety and tolerability.
| Metric | Value |
|---|---|
| Price | $0.57 |
| Market Cap | $10.92M |
| P/E Ratio | -0.10 |
| EPS | $-3.98 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.72 |
| 52-Week Low | $0.23 |
| Volume | 6.69K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.07M |
| Net Income | $-10.18M |
| Gross Margin | 0.00% |
ENSC analyst coverage data. Average price target: $0.00.